The MediWound Ltd. (NASDAQ:MDWD) Third-Quarter Results Are Out And Analysts Have Published New Forecasts

Last week, you might have seen that MediWound Ltd. (NASDAQ:MDWD) released its third-quarter result to the market. The early response was not positive, with shares down 6.5% to US$17.06 in the past week. Revenues of US$5.4m missed forecasts by 17%, but at least statutory losses were much smaller than expected, with per-share losses of US$0.24 coming in 70% smaller than what the analysts had forecast. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. So we gathered the latest post-earnings forecasts to see what estimates suggest is in store for next year.

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

Taking into account the latest results, the current consensus from MediWound's six analysts is for revenues of US$28.8m in 2026. This would reflect a sizeable 38% increase on its revenue over the past 12 months. Per-share losses are expected to explode, reaching US$2.48 per share. Yet prior to the latest earnings, the analysts had been forecasting revenues of US$29.6m and losses of US$2.50 per share in 2026.

See our latest analysis for MediWound

There was no real change to the average price target of US$31.50, suggesting that the revisions to revenue estimates are not expected to have a long-term impact on MediWound's valuation. The consensus price target is just an average of individual analyst targets, so - it could be handy to see how wide the range of underlying estimates is. Currently, the most bullish analyst values MediWound at US$39.00 per share, while the most bearish prices it at US$25.00. This shows there is still a bit of diversity in estimates, but analysts don't appear to be totally split on the stock as though it might be a success or failure situation.

One way to get more context on these forecasts is to look at how they compare to both past performance, and how other companies in the same industry are performing. One thing stands out from these estimates, which is that MediWound is forecast to grow faster in the future than it has in the past, with revenues expected to display 29% annualised growth until the end of 2026. If achieved, this would be a much better result than the 3.2% annual decline over the past five years. Compare this against analyst estimates for the broader industry, which suggest that (in aggregate) industry revenues are expected to grow 9.5% annually. Not only are MediWound's revenues expected to improve, it seems that the analysts are also expecting it to grow faster than the wider industry.

The Bottom Line

The most obvious conclusion is that the analysts made no changes to their forecasts for a loss next year. Regrettably, they also downgraded their revenue estimates, but the latest forecasts still imply the business will grow faster than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.

With that in mind, we wouldn't be too quick to come to a conclusion on MediWound. Long-term earnings power is much more important than next year's profits. At Simply Wall St, we have a full range of analyst estimates for MediWound going out to 2027, and you can see them free on our platform here..

Plus, you should also learn about the 2 warning signs we've spotted with MediWound .

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.